ARCTArcturus Therapeutics Holdi...

Nasdaq arcturusrx.com


$ 26.93 $ -1.40 (-4.94 %)    

Thursday, 09-May-2024 11:43:26 EDT
QQQ $ 440.93 $ 0.47 (0.11 %)
DIA $ 392.51 $ 2.40 (0.62 %)
SPY $ 518.94 $ 1.50 (0.29 %)
TLT $ 90.17 $ 0.13 (0.14 %)
GLD $ 215.80 $ 1.10 (0.51 %)
$ 27.21
$ 28.33
$ 0.00 x 0
$ 0.00 x 0
$ 26.90 - $ 28.58
$ 17.52 - $ 43.81
317,953
na
731.38M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 arcturus-therapeutics-q1-eps-100-beats-119-estimate-sales-3801m-beat-1754m-estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-arcturus-therapeutics-maintains-60-price-target

HC Wainwright & Co. reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price target.

 canaccord-genuity-maintains-buy-on-arcturus-therapeutics-raises-price-target-to-87

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target ...

 hc-wainwright--co-reiterates-buy-on-arcturus-therapeutics-maintains-60-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price ta...

 arcturus-therapeutics-q4-2023-gaap-eps-0320-beats-0760-estimate-sales-33989m-miss-37856m-estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.320) per share which beat the analyst consensus estimate o...

 earnings-scheduled-for-march-7-2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

 citigroup-maintains-buy-on-arcturus-therapeutics-raises-price-target-to-48

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target fro...

 arcturus-therapeutics-announces-new-covid-19-sa-mrna-results

Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferio...

 logitech-posts-q3-results-joins-coinbase-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.

 csl-and-arcturus-therapeutics-announced-the-publication-in-lancet-infectious-diseases-of-a-phase-3-study-showing-that-a-booster-dose-of-arct-154-meet-the-non-inferiority-criteria

Data follow approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine for Adults by Japan Mini...

 arcturus-therapeutics-lung-disease-candidate-triggers-bullish-rating-analyst-sees-over-200-upside

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine...

 canaccord-genuity-initiates-coverage-on-arcturus-therapeutics-with-buy-rating

Canaccord Genuity analyst Whitney Ijem initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating.

 hc-wainwright--co-reiterates-buy-on-arcturus-therapeutics-maintains-51-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $51 price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION